Prescient Therapeutics unveils novel adjuvant for enhancing cellular immunotherapy: CellPryme-A
CellPryme-A is the latest in a portfolio of platform cell technologies that can not only...
CellPryme-A is the latest in a portfolio of platform cell technologies that can not only...
Prescient Therapeutics (ASX: PTX) has presented exciting new data on CellPryme-A at the 7th Annual CAR-TCR...
The cancer drug market could be on the cusp of a timely renaissance as new...
Prescient Therapeutics Ltd (ASX:PTX) has been invited to present two sessions at the upcoming CAR-TCR Summit...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the...
Prescient will join with the US’s largest cancer centre with the goal of creating best-in-class,...
Prescient Therapeutics (ASX: PTX) takes a crucial step in advancing its next-generation cell therapy platform, OmniCAR. The...
Prescient Therapeutics (PTX) has partnered with the largest cancer centre in the US to create best-in-class,...
Prescient Therapeutics (ASX: PTX) has entered a strategic collaboration with the largest cancer centre in US...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.